• Fenofibrate is used to reduce cholesterol levels in people at risk of cardiovascular disease.
  • Fenofibrate reduces levels of low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels and triglycerides (TG) and increases levels of high-density lipoprotein (HDL).
  • Our fenofibrate Product is proposed in hard gelatin capsules filled with an innovative semi-solid matrix called Lidose® and is commercialized in numerous countries including the US market.
  • Clinical Trials : pharmacokinetic  and pharmacodynamic  studies vs. originator.

Publications :

  • Roger K. Verbeeck, Sophie De Niet, Sonia Lebrun, Mickael Tremege, Tim W. Rennie, Monte Coffiner, Bruno Streel and Bernard Cahay. The Lidose® Hard Capsule Formulation of Fenofibrate is Suprabioavailable Compared to the Nanoparticle Tablet Formulation Under High-fat Fed Conditions.